7 completed, 2 recruiting, 2 terminated. 7 Phase 2, 5 Phase 1, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 2, Recruiting 1 |
| Phase 1 | 5 | Completed 3, Terminated 2 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 1 | Recruiting 1 |
Follow Gamida Cell ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Motixafortide for MRD Sensitization in AML Motixafortide - Acute Myeloid Leukemia, Measurable Residual Disease | Phase 2 | Recruiting | Washington University School of Medicine | 10 | 2026-07-23 | 2026-07-24 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL GDA-201 - Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Gamida Cell ltd | 13 | 2022-07-05 | 2025-03-25 |
| Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies omidubicel - Hematological Malignancies | Phase 3 | Completed | Gamida Cell ltd | 36 | 2020-07-08 | 2026-06-22 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS NiCord® (omidubicel), Cord Blood Unit - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Gamida Cell ltd | 125 | 2016-12-16 | 2026-02-25 |
| Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies CordIn - Sickle Cell Disease, Thalassemia | Phase 1 / Phase 2 | Terminated | Gamida Cell ltd | 1 | 2016-04-04 | 2019-06-26 |
| Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients NiCord®/CordIn™ (omidubicel) - Patients Transplanted With NiCord/CordIn (Omidubicel) | Completed | Gamida Cell ltd | 33 | 2014-05-01 | 2024-10-23 | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM NiCord® - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Completed | Gamida Cell ltd | 36 | 2013-04-01 | 2020-10-22 |
| Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies NiCord - Sickle Cell Disease & Thalassemia | Phase 1 / Phase 2 | Completed | Gamida Cell ltd | 16 | 2012-09-01 | 2022-05-20 |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies NiCord® - Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | Completed | Gamida Cell ltd | 12 | 2010-11-01 | 2021-08-03 |
| Umbilical Cord Transplantation for the Elderly Population StemEx - Hematologic Malignancies | Phase 2 | Completed | Loyola University | 18 | 2010-01-01 | 2019-08-21 |
Hematologic Neoplasms (5) · Leukemia, Myeloid, Acute (4) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Sickle Cell (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Thalassemia (2) · Genetic Diseases, Inborn (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Neoplasm, Residual (1)
4-fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2 (S-S bridged) (1) · 4-fluorobenzoyl-TN-14003 (1) · Acetaminophen (1) · BKT140 (1) · Blood Component Removal (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Famotidine (1) · Loratadine (1) · Medrol Veriderm (1) · Methylprednisolone (1) · Niacinamide (1) · Specimen Handling (1) · auricularum (1) · dexamethasone 21-phosphate (1)
United States (11) · Netherlands (3) · Singapore (3) · Spain (3) · France (2) · Italy (2) · Brazil (1) · Israel (1) · Portugal (1) · United Kingdom (1)
Mitchell Horwitz, MD (4) · Joanne Kurtzberg, MD (2) · Patrick Stiff, MD (2) · Allistair Abraham, MD (1) · David Snyder, PhD (1) · Franco Locatelli, MD (1) · Jean-Hugues Dalle, MD (1) · Joel Brochstein, MD (1) · Joseph Rimando, MD (1) · Samuel Urrutia, MD (1)
PMID 22198152, PMID 24911148, PMID 30523748, PMID 33560399, PMID 33811823, PMID 34157093, PMID 37120136, PMID 37703995
P30CA138292 (1)